Jorge F Dimartino

US Patent:

6905669, Jun 14, 2005

Filed:

Apr 24, 2001

Appl. No.:

09/841744

Inventors:

Jorge F. DiMartino - San Carlos CA, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A61K049/00
C07H019/06

US Classification:

424 91, 536 285, 536 2851, 536 2852, 549511, 546113, 514 9, 514 11, 514449, 514459, 514460

Abstract:

Compositions and methods are provided for treating diseases associated with aberrant silencing of gene expression such as cancer by reestablishing the gene expression through inhibition of DNA hypomethylation and histone deacetylase. The method comprises: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.

US Patent:

7037900, May 2, 2006

Filed:

Oct 12, 2001

Appl. No.:

09/976468

Inventors:

Jorge DiMartino - San Carlos CA, US
John Tippett Nelson - Danville CA, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A01N 43/40
A61K 31/70

US Classification:

514 43, 514 42, 514 45, 514 49

Abstract:

Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of humans in vivo as well as for ex vivo conditioning of organ transplants in order to specifically suppress T-lymphocyte mediated immune responses while minimizing systemic toxicity of the drug.

US Patent:

7173016, Feb 6, 2007

Filed:

Aug 18, 2005

Appl. No.:

11/208046

Inventors:

Jorge DiMartino - San Carlos CA, US
John Tippett Nelson - Danville CA, US

Assignee:

Mayne Pharma (USA) Inc. - Paramus NJ

International Classification:

A01N 43/04
A61K 31/70
C07H 19/12

US Classification:

514 46, 514 42, 514 43, 514 45

Abstract:

Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of all forms of GVHD, especially steroid-refractory acute and chronic GVHD.

US Patent:

7276228, Oct 2, 2007

Filed:

Mar 15, 2005

Appl. No.:

11/082130

Inventors:

Jorge F. DiMartino - San Carlos CA, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A61K 49/00
C07H 19/06

US Classification:

424 91, 536 285, 536 2851, 536 2852, 549511, 546113, 514 9, 514 11, 514449, 514459, 514460

Abstract:

Methods are provided for treating hematological disorders by inhibition of DNA hypomethylation and histone deacetylase. Such disorders include, for example, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, and sickle cell anemia. The methods comprise: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.

US Patent:

20020114809, Aug 22, 2002

Filed:

Feb 21, 2001

Appl. No.:

09/790483

Inventors:

Joseph Rubinfeld - Danville CA, US
Lucy Chang - San Mateo CA, US
Jorge DiMartino - San Carlos CA, US

International Classification:

A61K039/00
A61K039/395
A61K031/57
A61K031/495

US Classification:

424/155100, 424/277100, 424/649000, 514/254070, 514/269000, 514/283000, 514/171000, 514/183000, 514/027000, 514/034000, 514/049000

Abstract:

Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent such as monoclonal antibody and interferon.

US Patent:

20040052864, Mar 18, 2004

Filed:

Jul 3, 2003

Appl. No.:

10/613222

Inventors:

Joseph Rubinfeld - Danville CA, US
Lucy Chang - San Mateo CA, US
Jorge DiMartino - San Carlos CA, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A61K048/00
A61K033/24
A61K031/7072

US Classification:

424/649000, 514/034000, 514/044000, 514/183000, 514/518000, 514/589000, 514/050000

Abstract:

Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent such as monoclonal antibody and interferon.

US Patent:

20040109846, Jun 10, 2004

Filed:

Oct 14, 2003

Appl. No.:

10/686047

Inventors:

Joseph Rubinfeld - Danville CA, US
Lucy Chang - San Mateo CA, US
Jorge DiMartino - San Carlos CA, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A61K038/20
A61K031/7072

US Classification:

424/085200, 514/050000

Abstract:

Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by restoring inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent is preferably a biologic agent such as an interleukin.

US Patent:

20040224919, Nov 11, 2004

Filed:

Jun 14, 2004

Appl. No.:

10/867621

Inventors:

Joseph Rubinfeld - Danville CA, US
Lucy Chang - San Mateo CA, US
Jorge DiMartino - San Carlos CA, US

International Classification:

A61K031/7072
C12Q001/68
A61K033/24

US Classification:

514/050000, 424/649000

Abstract:

Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent such as a platinum compound, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent.